Rigel Pharmaceuticals Inc
RIGL22.600USD
+0.690+3.15%
交易中 （美東）報價延遲15分鐘
403.79M總市值
10.86本益比TTM
關於 Rigel Pharmaceuticals Inc 公司
Rigel Pharmaceuticals, Inc. 是一家生物技術公司。該公司致力於開發和提供新型療法，以顯著改善血液病和癌症患者的生活。該公司專注於解決對疾病機制至關重要的信號通路的產品。其首款產品是 TAVALISSE（福他替尼二鈉六水合物）片劑，這是一種經批准的口服脾酪氨酸激酶抑制劑，用於治療對先前治療反應不足的慢性免疫性血小板減少症 (ITP) 成人患者。其第二款產品是 REZLIDHIA（奧魯他尼）膠囊，用於治療經 FDA 批准的檢測檢測出易感異檸檬酸脫氫酶-1 (IDH1) 突變的復發或難治性 (R/R) 急性髓細胞白血病 (AML) 成人患者。其產品 GAVRETO（pralsetinib）是一種每日一次的小分子口服激酶抑制劑，用於抑制轉染過程中重排的野生型 RET 和致癌 RET 融合。
公司簡介
公司代碼RIGL
公司名稱Rigel Pharmaceuticals Inc
上市日期Nov 29, 2000
CEOMr. Raul R. Rodriguez
員工數量162
證券類型Ordinary Share
年結日Nov 29
公司地址- -
城市- -
上市交易所NASDAQ Global Select Consolidated
國家- -
郵編- -
電話- -
網址- -
公司代碼RIGL
上市日期Nov 29, 2000
CEOMr. Raul R. Rodriguez
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
9.38K
+36.36%
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Raymond J. Furey
Mr. Raymond J. Furey
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Armistice Capital LLC
8.48%
Morgan Stanley & Co. LLC
8.28%
BlackRock Institutional Trust Company, N.A.
8.23%
Soleus Capital Management, L.P.
6.33%
The Vanguard Group, Inc.
5.75%
Other
62.92%
持股股東
持股股東
佔比
Armistice Capital LLC
8.48%
Morgan Stanley & Co. LLC
8.28%
BlackRock Institutional Trust Company, N.A.
8.23%
Soleus Capital Management, L.P.
6.33%
The Vanguard Group, Inc.
5.75%
Other
62.92%
股東類型
持股股東
佔比
Investment Advisor
28.57%
Investment Advisor/Hedge Fund
20.61%
Hedge Fund
18.26%
Research Firm
9.88%
Individual Investor
2.66%
Pension Fund
0.83%
Sovereign Wealth Fund
0.72%
Bank and Trust
0.14%
Venture Capital
0.09%
Other
18.22%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
289
14.62M
81.83%
+655.24K
2025Q1
295
14.90M
83.36%
+888.64K
2024Q4
281
12.77M
72.51%
-849.60K
2024Q3
291
12.41M
70.53%
-421.54K
2024Q2
303
10.88M
61.98%
-2.99M
2024Q1
319
11.57M
65.99%
-3.84M
2023Q4
326
11.03M
63.24%
-4.70M
2023Q3
343
11.50M
66.01%
-5.45M
2023Q2
356
11.96M
68.88%
-4.98M
2023Q1
359
12.15M
69.98%
-5.32M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Armistice Capital LLC
1.52M
8.48%
+364.00K
+31.60%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.48M
8.28%
-54.14K
-3.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.47M
8.23%
-33.13K
-2.20%
Mar 31, 2025
Soleus Capital Management, L.P.
1.13M
6.33%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.03M
5.75%
+15.14K
+1.49%
Mar 31, 2025
Capitolis Liquid Global Markets LLC
693.10K
3.88%
+693.10K
--
Mar 31, 2025
State Street Global Advisors (US)
637.03K
3.56%
+256.52K
+67.41%
Mar 31, 2025
Acadian Asset Management LLC
565.04K
3.16%
+188.68K
+50.13%
Mar 31, 2025
Geode Capital Management, L.L.C.
411.17K
2.3%
+9.12K
+2.27%
Mar 31, 2025
CM Management, LLC
250.00K
1.4%
+7.50K
+3.09%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
0.75%
Zacks Small/Mid Cap ETF
0.6%
ALPS Medical Breakthroughs ETF
0.23%
SPDR S&P Biotech ETF
0.09%
iShares Micro-Cap ETF
0.07%
Vanguard US Momentum Factor ETF
0.06%
Direxion Daily S&P Biotech Bull 3X Shares
0.05%
Vanguard US Multifactor ETF
0.05%
Franklin US Small Cap Multifactor Index ETF
0.04%
Principal U.S. Small-Cap ETF
0.04%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比0.75%
Zacks Small/Mid Cap ETF
佔比0.6%
ALPS Medical Breakthroughs ETF
佔比0.23%
SPDR S&P Biotech ETF
佔比0.09%
iShares Micro-Cap ETF
佔比0.07%
Vanguard US Momentum Factor ETF
佔比0.06%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.05%
Vanguard US Multifactor ETF
佔比0.05%
Franklin US Small Cap Multifactor Index ETF
佔比0.04%
Principal U.S. Small-Cap ETF
佔比0.04%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
公告日期
類型
比率
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
Jun 25, 2024
Merger
10<1
